Recent Quotes (30 days)

You have no recent quotes
chg | %

Response Biomedical Corp  

(Public, TSE:RBM)   Watch this stock  
Find more results for RBM
0.000 (0.00%)
Apr 13 - Close
TSE data delayed by 15 mins - Disclaimer
Currency in CAD
Range     -
52 week 0.66 - 1.89
Open     -
Vol / Avg. 355.00/1,171.00
Mkt cap 7.50M
P/E     -
Div/yield     -
EPS -0.27
Shares 9.76M
Beta -3.07
Inst. own     -
May 19, 2015
Response Biomedical Corp Annual Shareholders Meeting Add to calendar
May 11, 2015
Q1 2015 Response Biomedical Corp Earnings Release - 4:00PM EDT - Add to calendar
Mar 16, 2015
Q4 2014 Response Biomedical Corp Earnings Call - Webcast
Mar 16, 2015
Q4 2014 Response Biomedical Corp Earnings Release

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin 8.27% -18.98%
Operating margin -34.13% -45.70%
EBITD margin - -36.67%
Return on average assets 8.13% -15.02%
Return on average equity - -
Employees 65 -
CDP Score - -


1781 75th Ave W
+1-604-4566010 (Phone)
+1-604-4566066 (Fax)

Website links


Response Biomedical Corp. (Response) is engaged in the research, development, commercialization and distribution of diagnostic technologies for the medical central-lab testing, point of care (POC) testing and on-site environmental testing markets. The Company develops, manufactures and sells its RAMP system for the global medical point of care market, including cardiovascular testing, infectious disease testing market and the on-site environmental testing market, including biodefense and vector environmental testing. In the United States, its RAMP 200 Reader is limited to central-lab use with the cardiovascular tests. POC, on-site diagnostic tests (or assays), are non-laboratory based tests performed using portable hand-held devices, compact desktop analyzers, single-use test cartridges and/or dipsticks RAMP represents a paradigm in diagnostics that provides information in minutes.

Officers and directors

William J. Adams Chief Financial Officer, Corporate Secretary
Age: 51
Barbara Kinnaird Ph.D. Chief Operating Officer
Age: 46
Zheng Wang General Manager, Asia Pacific
Lewis J. Shuster Chairman of the Board
Anthony F. Holler M.D. Interim Chief Executive Officer, Director
Age: 61
Peter A. Thompson M.D. Director
Jonathan Wang Ph.D. Director
Age: 45
Joseph D. Keegan Ph.D. Independent Director
Clinton H. Severson Independent Director
Age: 66
David Guowei Wang Independent Director
Age: 51